The paper appeared a few months before the EMPA-REG OUTCOME trial revealed the potential of a new drug class, the SGLT2 inhibitors, in preventing hospitalization for heart failure.
Welcome to Paper of the Week, which looks back at research and commentary of the past 25 years in The American Journal of Managed Care® and why it matters today.
This week’s paper comes from our January 2015 issue. The authors of “Disease-Modifying Therapy and Hospitalization Risk in Heart Failure Patients” discuss the high cost of heart failure to the health system. They found that some treatments, such as ACE inhibitors or ARBs, had potential in preventing heart failure in Medicaid patients in managed care, but the projected savings were relatively modest.
The paper appeared a few months before the EMPA-REG OUTCOME trial revealed the potential of a new drug class, the SGLT2 inhibitors, in preventing hospitalization for heart failure.
For the full paper, visit ajmc.com.
Managed Care Reflections: A Q&A With Jan E. Berger, MD, MJ
January 7th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The January issue features a conversation with longtime editorial board member Jan E. Berger, MD, MJ, the CEO of Health Intelligence Partners.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen